A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities

Br J Haematol. 2017 Sep;178(5):820-823. doi: 10.1111/bjh.14171. Epub 2016 Jul 5.
No abstract available

Keywords: bendamustine; chronic lymphocytic leukaemia; comorbidities.

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / administration & dosage
  • Comorbidity
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Rituximab / administration & dosage
  • Treatment Outcome

Substances

  • Rituximab
  • Bendamustine Hydrochloride